Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Jul 10. pii: canimm.0755.2017. doi: 10.1158/2326-6066.CIR-17-0755. [Epub ahead of print]

PMID:
29991499
2.

High prevalence of colon adenomas in end-stage kidney disease patients on hemodialysis undergoing renal transplant evaluation.

Saumoy M, Jesudian AB, Aden B, Serur D, Sundararajan S, Sivananthan G, Gambarin-Gelwan M.

Clin Transplant. 2016 Mar;30(3):256-62. doi: 10.1111/ctr.12684. Epub 2016 Jan 30.

PMID:
26714740
3.

Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations.

Torres HA, Chong PP, De Lima M, Friedman MS, Giralt S, Hammond SP, Kiel PJ, Masur H, McDonald GB, Wingard JR, Gambarin-Gelwan M.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1870-82. doi: 10.1016/j.bbmt.2015.07.033. Epub 2015 Aug 6. Review. No abstract available.

4.

FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.

Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH.

BMC Gastroenterol. 2014 Jul 3;14:118. doi: 10.1186/1471-230X-14-118.

5.

Viral hepatitis, non-alcoholic fatty liver disease and alcohol as risk factors for hepatocellular carcinoma.

Gambarin-Gelwan M.

Chin Clin Oncol. 2013 Dec;2(4):32. doi: 10.3978/j.issn.2304-3865.2013.09.02.

6.

Advances in the treatment of hepatitis C virus infection.

Jesudian AB, Gambarin-Gelwan M, Jacobson IM.

Gastroenterol Hepatol (N Y). 2012 Feb;8(2):91-101.

7.

Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.

Gambarin-Gelwan M, Jacobson IM.

Curr Gastroenterol Rep. 2012 Feb;14(1):47-54. doi: 10.1007/s11894-011-0237-1. Review.

PMID:
22161022
8.

Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?

Gambarin-Gelwan M, Jacobson IM.

J Hepatol. 2011 Sep;55(3):505-506. doi: 10.1016/j.jhep.2011.04.001. Epub 2011 Apr 15. No abstract available.

9.

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.

Gambarin-Gelwan M, Jacobson IM.

J Viral Hepat. 2008 Sep;15(9):623-33. doi: 10.1111/j.1365-2893.2008.01018.x. Epub 2008 Jul 10. Review.

PMID:
18637069
10.

Hepatitis B in pregnancy.

Gambarin-Gelwan M.

Clin Liver Dis. 2007 Nov;11(4):945-63, x. Review.

PMID:
17981236
11.

Mesalamine-induced Pneumonitis and Serum Sickness-like Reaction.

Harris A, Eswaran S, Bosworth B, Gambarin-Gelwan M, Scherl EJ.

Gastroenterol Hepatol (N Y). 2007 Nov;3(11):875-7. No abstract available.

12.

Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W.

Clin Gastroenterol Hepatol. 2007 Apr;5(4):496-501. Epub 2007 Feb 6.

PMID:
17287148
13.

Percutaneous Liver Biopsy.

Gambarin-Gelwan M.

Gastroenterol Hepatol (N Y). 2006 Sep;2(9):689-690. No abstract available.

14.

Cancer history and other personal factors affect quality of life in patients with hepatitis C.

Olson SH, Iyer S, Scott J, Erez O, Samuel S, Markovits T, Schwartz M, Toro C, Gambarin-Gelwan M, Kurtz RC.

Health Qual Life Outcomes. 2005 Jun 16;3:39.

15.

Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation.

Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD.

Am J Gastroenterol. 2000 Jun;95(6):1535-8.

PMID:
10894592

Supplemental Content

Loading ...
Support Center